Alev KURAL, Tülay OMMA, Ahmet OMMA, Namık YİĞİT, Hatice SEVAL, Macit KOLDAŞ

The association of TAFI (Thrombin-activatable fibrinolysis inhibitor) with insulin resistance and components of metabolic syndrome in patients with metabolic syndrome

To investigate the association of TAFI with components of metabolic syndrome and insulin resistance in patients with metabolic syndrome. Materials and methods: Patients between 20 and 70 years of age, who met at least 3 of the metabolic syndrome criteria, and had no known coronary artery disease were included in the study. The control group consisted of 20 healthy subjects with demographic characteristics similar to the patients. Fasting blood glucose, HbA1c, lipid profile, insulin, microalbumin, and TAFI Ag levels were investigated in the patients and controls. Insulin resistance was calculated according to the HOMA-IR [(fasting plasma insulin (mIU/ml) x fasting plasma glucose (mmol/L))/22.5] formula. Results: There was a significant difference (P < 0.01) between patients with metabolic syndrome (MS) and healthy individuals with respect to TAFI Ag levels. However, when patients with MS were divided into 2 groups according to HOMA-IR values, an indicator of insulin resistance, no association was detected between the levels of HOMA-IR and TAFI Ag. In metabolic syndrome group, there was a positive correlation only between the triglyceride and plasma TAFI Ag levels (P < 0.05). Conclusion: These findings suggest that increased TAFI levels in metabolic syndrome may contribute to prothrombotic state and impaired fibrinolysis, and that hypertriglyceridemia may play part in this process.

Anahtar Kelimeler:

Key words: Metabolic syndrome, TAFI, insulin resistance

The association of TAFI (Thrombin-activatable fibrinolysis inhibitor) with insulin resistance and components of metabolic syndrome in patients with metabolic syndrome

Keywords:

Key words: Metabolic syndrome, TAFI, insulin resistance,

PDF

___

Markx PF, Verkleij CJ , Seron MV, Meijers JC. Recent developments in thrombin activable fibrinolysis inhibitor research.Mini Rev Med Chem. 2009 Sep;9(10):1165-73. 6. Wang W, Hendriks DF, ScharpeSS. Carboxypeptidase U, plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44 7. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol. 2000 Dec; 20(12): 2511-8.
van Tilburg NH, Rosendaal FR, Bertina RM: Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000 May 1; 95(9): 2855–9. 9. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660–665.
Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 1: 791–797.
Hataji O, Taguchi O,Gabazza EC. Increased circulating levels of TAFI in lung cancer patients. J Haematol 2004; 76: 214-9.
Parisi V, Capasso F, Pudore L. New thrombophilia markers in digestive tract neoplasia. Tumori 2003; 89: 129-32.
Moijers JC, Oudijk EJ, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK et al. Reduced activity of TAFI in acute promyelocytic leukemia. Br J Haematol. 2000 ; 108: 518-23.
Demirkan B, Ozcan MA, Glu AA. The effect of antracyline- based adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer. Clin Appl Thromb Hemost 2006; 12: 9-14.
Juhan-Vague, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y et al. Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors. Arterioscler Thromb Vasc Biol 2000; 20: 2156-2161.
Mosnier LO, von dem Borne PA, Meijersic, Bouma BN. Plasma TAFI levels influence the clot time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-835.
Hideo Wada, Tsutomu Nobori, Rica Watanable, Hiroshi Shku, Nobuo Sakurogawa. Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC). Turk J. Haematol 2002; 19(2):235-237.
Yasuko Hori, Esteban C. Gabazza, Yukata Yano, Akira Katsuki, Koji Suzuki, Yukihinko Adachi et al. Insulin Resistance Is Associated with Increased Circulating Level of Thrombin- Activatable Fibrinolysis Inhibitor in Type 2 Diabetic Patients. J Clin Endocrinol Metab 2002; 87: 660-665.
Amparo Santamaria, Antonio Martinez-Rubio, Montserrat Borrell, Jose Mateo,Rosa Ortin, Jordi Fontcuberta. Risk of acute Coronary Artery Disease associated with functional Thrombin Activatable Fibrinolysis Inhibitor plasma level. Haematologica 2004; 89: 880-881.